Super Liver: All 35 enrolled participants self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each), taken in the morning with breakfast, for 12 consecutive weeks.
Study summary
This is a decentralized (fully virtual), single-group, open-label, prospective clinical trial evaluating the effects of Super Liver Liquid Drops, a liquid botanical dietary supplement, on gut health, digestive comfort, energy levels, and overall well-being over 12 weeks. All 35 enrolled participants will self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each) in the morning with breakfast for the full 12-week intervention period.
Participants will complete validated questionnaires and self-reported assessments at Baseline, Week 2, Week 4, Week 8, and Week 12 via the Citruslabs study platform. All study activities will be conducted remotely.
Eligibility
Sex
ALL
Min age
30 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Be male or female.
* Be aged 30-65 years (inclusive) at the time of enrollment.
* Over the past four weeks, has had concerns regarding low energy levels and at least two of the following: Bloating, Digestion, Irregular Bowel movements, Brain fog.
* Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
* Willing and able to follow the study protocol as described.
* Willing to maintain their current diet, exercise routine, and sleep patterns, for the duration of the trial.
* If taking other over-the-counter supplements or herbal remedies is willing to maintain this routine without introducing any other new products for the study duration.
* Resides in the United States.
* Willing to follow the study protocol as described.
Exclusion Criteria:
* Known allergy or sensitivity to any of the study product ingredients (milk thistle, dandelion, yellow dock, turmeric, ginger, chicory/inulin, berberine).
* Known history of severe digestive disorders like acid reflux, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), Crohn's disease, or gastrointestinal tract surgeries.
* Known history of gallbladder disease or bile duct obstruction.
* Has a chronic health condition that could impact participation in this study, such as oncological or psychiatric disorders.
* Has a planned surgery in the next 12 weeks.
* Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
* Known history of substance abuse.
* Currently, or was in the past 3 months, a smoker.
* Currently participating in or planning to participate in another research study during the study period.
Primary outcome measure(s)
Change in Gastrointestinal Symptom Rating Scale (GSRS) — Baseline to Week 12 Change from baseline to Week 12 in gastrointestinal symptom severity as assessed by the Gastrointestinal Symptom Rating Scale (GSRS). Higher scores indicate greater gastrointestinal symptom severity.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.